Concentrating on the pharma space, Bino Pathiparampil of IIFL Capital told CNBC-TV18 the success of Biocon‘s oral insulin product deal would be a positive for the company. He also has a buy on Dr Reddy‘s and believes it should give a 25 percent plus upside in the next one year.
first published: Nov 20, 2012 12:20 pm
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.

